Alveolar rhabdomyosarcoma (ARMS) is a rare soft-tissue malignancy constituting less than 1% of soft-tissue sarcomas. In this article we are describing a rare case of ARMS arising in the paranasal sinuses of an adult patient. We emphasize the multidisciplinary treatment administered, thanks to which the patient remains alive and free of disease for six years after the initial diagnosis
Introduction
Alveolar rhabdomyosarcoma (ARMS) is a rare soft-tissues malignancy constituting less than 1% of soft-tissue sarcomas (1) . About 25% of those occur in the head and neck, where typical sites include orbit, soft tissues of the cheek and paranasal sinuses (2) It primarily affects children and adolescents however it also occasionally occurs in adults.
We describe a rare case of ARMS arising in the paranasal sinuses of an adult patient.
Case report
A 65-year-old woman was presented to our hospital with a year-long history of oppressive headaches. Her past history was otherwise unremarkable. showed an aggressive mass in the left ethmoidal sinus ( Figure   1 ). In addition, there were retropharyngeal and upper jugular lymphadenopathies. PET-CT ruled-out distance metastasis.
Fine-needle aspiration showed an undifferentiated carcinoma.
Microscopic examination of the biopsy specimen revealed a rounded-cell solid tumour, which had grown into solid nest and cords separated by fibrous septa, defining an alveolar pattern.
To confirm the diagnosis, FISH analysis was then performed to evaluate for that FKHR gene (13q14) break (Figure 2 ). 
Discussion
Rhabdomyosarcoma (RMS) is a high-grade neoplasm of mesenchymal originates from theprimitive skeletal muscle cells. It is the most common soft tissue sarcoma in childhood and adolescence, but it is extremely rare in adults (3) . Alveolar RMS is an aggressive subtype with a distinct histology, containing small and rounded cells. Typically, ARMS is rare in the head and neck, and occurs in the deep soft tissues of the lower extremities. Their natural clinical course is indolent and slow usually, presenting functional impairment or as a slowly enlarging mass, as seen in our case (4) . Haematogenous spread is the typical route of metastasis, the lung being the most common site in 40-60% of cases. However, lymphatic metastases are also seen in around 7-10% of cases. (5) . The two major histological subtypes of RMS are alveolar RMS, driven by the fusion protein PAX3-FKHR or PAX7-FKHR, and embryonic RMS, which is usually genetically heterogeneous (6) .
Effectively, ARMS have a characteristic translocation t (2;13), fusing the PAX3 gene (regulate transcription during neuromuscular development) with the FKHR gene (a member of the family of transcription factors). It is hypothesized that this fusion transcription factor inappropriately activates transcription of the genes that contribute to a transformed phenotype (5) . In the same way, the rupture of the FKHR gene has been associated to this histology, as seen in our case.
Because of their extreme rarity, inclusion of the ARMS subtype in the differential diagnosis of small round cell tumors of the head and neck region in patients over the age of 45 years is often neglected.
Due to the rarity of ARMS of the head and neck, having only Despite treatment improvements, the long-term prognosis for ARMS has remained poor due to the high rate of metastatic disease, being 71% at five years for patients presenting with localized disease, dropping to 20% for patients presenting with metastases. The local recurrence rate has been similar, ranging from 10-25%. In our case, our patient obtained 3-years diseasefree with the initial therapy and the same treatments were included in the recurrence, obtaining major response again. Now after 5 years, the patient is alive with no local or distance disease.
The rarity of ARMS in the head and neck region and the smaller clinical series make it difficult to determine prognostic factors for survival.
Conclusion
In conclusion, our study reports a rare case of ARMS in an infrequent location. Due to the uncommon natural of the disease, diagnosis can be difficult, and analyses of the histopathology and molecular profile features are necessary for confirmation. The optimal treatment for ARMS has not yet been clearly elucidated.
A multidisciplinary approach to these patients with surgery, radiotherapy and chemotherapy is the best current therapy, though long-term survivals remains poor.
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No known conflict of interest. isolated case reports, the optimal treatment plan has not been clearly elucidated. Multimodality treatment protocols, including surgery, radiotherapy and chemotherapy, have improved the outcome over recent decades (6, 7) . Local control is the main objective in the treatment of head and neck RMS. Like most soft tissues sarcomas, the main treatment of primary ARMS is complete surgical removal using a wide-local excision. The goal of obtaining negative margins after surgical resection has been shown to increase local control and survival rates. Typically, neck dissection is only utilized when palpable nodes are present, rather than prophylactically. Depending on the tumor location, disease extension and the Center experience, endoscopic surgery can be used (8) .
Radiation therapy plays an important role in the treatment of ARMS (9) . It is used to control local microscopic or gross residual disease in such instances, in cases where head and neck localization tumours often cannot be completely removed with surgery.
Early guidelines recommended dosage as high as 55 to 60 Gy for control of the primary tumour. General radiation therapy guidelines have evolved with sequential intergroup studies, concluding that for residual microscopic disease 40-45 Gy appears to be sufficient to achieve local control and 45-50 Gy for gross residual disease.
The development of adjuvant and neoadjuvant chemotherapy has increased survival rates in patients with localized disease to approximately 60%. Combination agents for known activity in the rhabdomyosarcoma include ifosfamide, vincristine, doxorubicine and cyclofosphamida (10, 11) . The initial approach of our multidisciplinary tumour board was neoadjuvant chemotherapy, due to the unresectability of initial tumour, following surgical excision of the mass and ipsilateral neck dissection. The section margins were affected, so adjuvant radiotherapy was Figure 4 . Radiotherapy treatment. Figure 5 . MR-T2 .Tumour recurrence.
